The Online Investor
Assertio Therapeutics Inc (DEPO)

Depomed is a pharmaceutical company focused on pain and other central nervous system conditions. Co.'s business includes the following products marketed in the U.S. for various pain states: Gralise®, which is a once-daily product for the management of postherpetic neuralgia; CAMBIA®, which is a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; Zipsor®, which is a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain; NUCYNTA® ER, which is a product for the management of pain severe enough to require daily, including neuropathic pain; and NUCYNTA® IR, which is for the management of moderate to severe acute pain in adults.
Company Name: 
Assertio Therapeutics Inc
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree DEPO Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (3.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Assertio Therapeutics Inc (DEPO) Page | The Online Investor Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.